Merck and Curon Biopharmaceutical, a privately held biotech company, have entered into a definitive agreement under which Merck, through a subsidiary, will acquire CN201, an investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, for $700 million upfront. Curon is also eligible to receive as much as $600 million in milestone payments associated development and regulatory approval of CN201.   CN201 is currently being evaluated in Phase 1 and Phase 1b/...